0001415889-24-021731.txt : 20240820 0001415889-24-021731.hdr.sgml : 20240820 20240820184623 ACCESSION NUMBER: 0001415889-24-021731 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240816 FILED AS OF DATE: 20240820 DATE AS OF CHANGE: 20240820 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schneyer Mark C. CENTRAL INDEX KEY: 0001899977 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 241226758 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-08202024_100820.xml X0508 4 2024-08-16 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001899977 Schneyer Mark C. C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 false true false false EVP, CHIEF FINANCIAL OFFICER 0 Common Stock 2024-08-16 4 A 0 5275 0 A 39839 D Common Stock 2024-08-16 4 A 0 13629 0 A 53468 D Common Stock 2024-08-19 4 S 0 9733 15.28 D 43735 D Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Jennifer J. Rhodes, Attorney-in-Fact 2024-08-20